INTRODUCTION

Atrial fibrosis is an inevitable pathological mechanism in several different cardiac diseases, especially atrial fibrillation (AF), which can lead to cerebral apoplexy and frequent hospitalizations.1,2 We have previously demonstrated that homocysteine (Hcy) is significantly associated with the recurrence of AF after radiofrequency ablation.3 Elevated levels of Hcy in plasma are an independent risk factor for cardiovascular disease, and most cardiovascular conditions accompanied by hyperhomocysteinemia are significantly correlated with cardiac fibrosis. This indicates that high Hcy may promote atrial fibrosis.4 Structural remodelling in atrium can be easily detected in paroxysmal and permanent AF rather than pathological changes in ventricle. Similarly, cardiac fibrosis is accompanied by heart failure...
(HF) due to the accumulation of collagen fibres, such that patients with AF have HF with a preserved ejection fraction (HFrEF) rather than HF with reduced ejection fraction (HFpEF), accounting for 30% of cases.5–7 These findings suggest that the atrial fibrosis is associated with collagen metabolism and is involved in the mechanism of AF. Furthermore, hyperhomocysteinemia is a pathological feature in the aetiology of atrial fibrosis, although the underlying mechanisms remain unclear.8 Hcy, as a stimulus, can bind to G protein couple receptors (GPCRs) and regulate the phospholipase C (PLC) activation, producing intracellular messengers, 1,2-diacylglycerol (DAG); it recruits protein kinase C (PKC) and subsequently effecting the downstream signalling pathway of cardiac fibrosis.9 Canonical transient receptor potential receptor 3 (TRPC3) is an indispensable factor in regulating the mechanisms of fibrosis development and in promoting the transition of fibroblasts into myofibroblasts with an adverse influence on the modulation of collagen.10 Interestingly, TRPC3 is directly activated by PKC phosphorylation. We speculated that Hcy could trigger TRPC3 to mediate the mechanism of atrial fibrosis. On the other hand, sirtuin-1 (SIRT1) appears to function as an anti-fibrotic protein. Recently, the progression of myocardial fibrosis has been shown to simultaneously activate the renin-angiotensin system (RAS). This causes myocardial apoptosis through the TGF-β pathway and controls the aggregation of monocytes and fibroblasts, following with the down-regulation of SIRT1.11 It remains unclear that whether TRPC3 and SIRT1 can control and modulate the fibrotic system to reciprocally affect cardiac structural remodelling under Hcy stimulation. In an attempt to address this issue, we hypothesize that TRPC3 is a novel regulator of SIRT1 in modulating the TGF-β pathway. In addition, our study aim to elucidate whether SIRT1 is directly involved in the process of TRPC3 mediated atrial fibrosis and its role in fibrobust proliferation and differentiation under high Hcy conditions.

2 | METHOD DETAILS

2.1 | Human tissue specimens

Tissue samples were obtained from the left atrial appendage of 30 patients. All samples were collected at the Second Affiliated Hospital of Nanchang University between January 2016 and September 2017. The sinus rhythm (SR) group comprised patients with sinus rhythm and preserved left ventricular function (n = 12); the AF group comprised patients with atrial fibrillation and rheumatic mitral stenosis (n = 18). The study protocol was approved by the Institutional Review Board of the Second Affiliated Hospital of Nanchang University, and all participates gave informed consent (Permit Number: 2016-022). Detailed clinical and pathological information on the patients is summarized in Table 1.

2.2 | Animal model

All animal experiments were approved by the SLAC Labomouseery Animal Co. Ltd, Hunan, China. Mice were kept on a 12 hours light/12 hours dark cycle at a room temperature of 20-25°C, with a relative humidity of 40%-70%. Baseline information on male C57B6 mice (n = 60) was detected by transthoracic echocardiography. All experienced mice underwent transverse aortic constriction (TAC) at four weeks of age following randomization. Mice in the high-Hcy (HH) diet group were fed a high-Hcy diet (AIN-76A + 4% methionine with folic acid and high-Hcy mixed diet classed as HH+FC group (Table 2). Mice in the HH group received the same dose of saline by intraperitoneal injection and underwent sham surgery. These mice were fed a folic acid and high-Hcy mixed diet classed as HH+FC group (Table 2).

2.3 | Transthoracic echocardiography

Mice were anaesthetized with 5% isoflurane for transthoracic echocardiography, which was performed using a Vevo2100 imaging system (VisualSonics). Ejection fraction (EF) was regarded as a systolic parameter, and E/A and E/E’ ratios were regarded as diastolic markers via baseline echocardiography. Pulsed-wave Doppler and tissue Doppler were performed to detect the peak ratio of E/A and E/E’ in the three groups at 4,7 and 16 weeks. Left ventricular (LV) end-diastolic volume (EDV) and end-systolic volume (ESV) were obtained by the Simpson method of disks. Ejection fraction was calculated as EF (%) = (EDV − ESV)/EDV × 100% and was used to determine systolic function from images in the parasternal short-axis view as previously described.12 The mice in the HH group received the same dose of saline by intraperitoneal injection and underwent sham surgery. These mice were fed a folic acid and high-Hcy mixed diet classed as HH+FC group (Table 2).

### Table 1: Comparison the patients between AF and SR

|                          | AF patients (N = 18) | SR patients (N = 12) | P value (AF vs SR) |
|--------------------------|----------------------|----------------------|-------------------|
| Age: mean ± SEM          | 55.8 ± 4.3           | 55.8 ± 2.8           | .98               |
| QTc prolongation         | 18 (13)              | 12 (5)               | .078              |
| Fibrosis                 | 18 (17)**            | 12 (2)               | <.0001            |
| Gender: N (%) Female     | 18 (10)              | 12 (7)               | .289              |
| Elevated baseline heart rate | 18 (7)           | 12 (2)               | .147              |
| Hypertension: N (%) with history | 18 (4)     | 12 (3)               | .331              |
| Hyperhomocysteinemia (history) | 18 (5)      | 12 (1)               | .173              |
| Heart failure: N (%) with history | 18 (7)     | 12 (3)               | .109              |
| Sudden death rate: N (%) with history | 18 (1)     | 12 (0)               | .6                |

Note: The relevant cardiac diseases and baseline data in the patients with SR or AF. Abbreviations: AF, atrial fibrillation; SR, sinus rhythm.
formula: FS (%) = (LVEDD − LVESD)/LVEDD × 100%. The E/A ratio was determined to evaluate diastolic function in pulse-doppler Doppler mode. TAC mice demonstrated diastolic dysfunction by echocardiography, including both the NH and HH groups.

2.4 Surface electrocardiography

Surface electrocardiography (ECG) was recorded prior to in vivo arrhythmia induction studies for HH, NH and SH mice at 16 weeks of age. The PR interval, QRS dimension, QT interval and RR interval were measured three times and averaged on MedLab6 software (Biological signal acquisition and processing system, Beijing, China).

2.5 Histopathological examination

Atrial tissues were fixed in 4% paraformaldehyde, embedded in paraffin wax and underwent different staining methods, including haematoxylin-eosin (HE), Masson and immunohistochemical (IHC) staining, each according to the manufacturer’s instructions (Sigma-Aldrich). Primary antibodies were used anti-TGF-β (5 μg/mL) (CST, 3711) and anti-collagen-I (anti-Col-I 5 μg/mL) (Thermo Fisher Scientific, PA5-16697). For electron microscopy, heart tissues were fixed with special fixative at 4°C for 2-4 hours and rinsed three times with 0.1 mol/L phosphate buffer (PB). Next, the tissues were fixed with 1% osmium acid, rinsed with 0.1 mol/L PB (pH = 7.4) and dehydrated with ascending ethanol concentrations for 15 minutes each time. The tissues were immersed in Epon B12 resin/acetone (1:1) for 2-4 hours, immersed in fresh Epon B12 resin for 30 minutes and embedded for overnight at 60°C. The sample was cut to an approximately 60-80 nm thickness using a ultrathin section machine, subjected to uranium-lead double-staining (2% uranium acetate saturated alcohol solution, lead citrate, 15 minutes staining) and observed on a transmission electron microscope (HT-7700, Hitachi).

2.6 Immunofluorescence and immunohistochemistry

Immunofluorescence (IF): For conventional fixation, cells were immersed in 4% polyoxymethylene and 0.1% Triton X-100, washed three times with sterile phosphate-buffered saline (PBS), and incubated with primary antibodies in PBS containing 5% bovine serum albumin (BSA) at 4°C overnight. After the samples were washed three times with PBS, they were incubated with Alexa 488- or 564-conjugated goat anti-rabbit/mouse secondary antibodies at room temperature for 1.5 hours. Finally, each group of cells was stained with 4’,6-diamidino-2-phenylindole (DAPI). To detect the localization of SIRT1 and TRPC3 under Hcy stimulation, HA-SIRT1 and Flag-TRPC3 were over-expressed in HEK 293 cells, which were treated with or without Hcy (500 μmol/L) for 48 hours. Representative images were acquired using a BWS435 confocal microscope, and LAS AF Lite software was used for professional image analysis (Zeiss).

Immunohistochemistry: Tissue sections were incubated in 10 mM citric acid buffer (pH 6.0) at boiling temperatures for 8 minutes, placed in PBS (pH 7.4), washed three times on a decolouring shaker and incubated with 3% BSA for 30 minutes at room temperature. Sections were incubated with primary antibody (1:100) at 4°C in a wet box overnight, and the antigen-antibody reaction was observed using a horseradish peroxidase (HRP)-conjugated secondary antibody after incubation for 50 minutes. Image acquisition was performed using an XSP-C204 microscope (CIC).

2.7 Cell lines and treatment

MCF and HEK-293T cell lines were purchased from Procell Life Science and Technology (CP-M074 MCF) and American Type Culture Collection (CRL-3216 293T) between 2016 and 2017. The cells used in this study were cultured in DMEM medium (#11960051) (Gibco) supplemented with 10% foetal bovine serum (#10099-141) (Gibco). Pyrazole-10 (Pyr-10, HY-19408), Resveratrol (Res, HY-16561) and Salermide (Sal, HY-101073) were purchased from MedChemExpress, and Hcy (H-4628) was obtained from Sigma-Aldrich.

2.8 Isolation of mouse atrial fibroblast

Mouse atrial fibroblasts were collected and cultured from neonatal C57B6 mice at 0-2 days (Slake, Hunan, CHINA), weighing 3-5 g, in order to identify the relationship between atrial fibrosis and Hcy. The specific methods for mouse atrial fibroblast culturing are as follows. Firstly, mice were disinfected, and the neonatal heart was rapidly removed. Left and right ventricles with a magnifying glass were carefully removed. The sample was cut into small pieces using a pair of tweezers and subjected to digestion with a trypsin/Collagenase II mixture three times, followed by treatment with a serum-containing medium that inhibited enzyme activity. The cell suspension was centrifuged (500 g, 15 minutes) it, collected and plated. Cells were allowed to adherence for 2 hours in a CO₂ incubator.

2.9 Lentivirus infection

The Lenti-TRPC3-shRNA Tet-On construct (VB171023-1015pst) for TRPC3 knockdown was generated, packed and purified by VectorBuilder. The TRPC3-shRNA target sequence
was 5′-CCTAAGGTTAAGTCGCCCTCG-3′. The final product was Puro-U6>mTrpc3. The empty vector used was puro-U6>Scramble. The scramble target sequence was 5′-CCTAAGGTTAAGTCGCCCTCG-3′. For SIRT1 overexpression or empty vector (Ad-GFP), SIRT1 overexpression or lentivirus plasmids inhibiting TRPC3 (Ad-TRPC3-shRNA), 12 hours before TAC or sham surgery.16 Mice in the SIRT1-overexpression or lentivirus plasmids inhibiting TRPC3 (Ad-TRPC3-shRNA), 12 hours before TAC or sham surgery.16 Mice in the SIRT1-overexpression or empty vector (Ad-GFP) at a multiplicity of infection of 20 (MOI = 20). The infection efficiency was determined by GFP fluorescence intensity (90%-95%).

2.10 | Cell proliferation analysis

Cardiac fibroblasts were cultured in T25 culture flask (2.0 × 10^5 cells/flask, 25 cm² growth area) for each treatment group. Cells were harvested after trypsinization and seeded on gelatin-coated 96-well plates (1 × 10⁴ cells/well). Fibroblasts were treated with serum-deprived medium for 24 hours under Hcy stimulation at 0, 50, 200, 500 and 1000 μmol/L concentrations of Hcy. Next, each well was incubated with cell counting kit-8 (CCK-8) solution (100 μL) for 2 hours. The absorbance was read using a spectrophotometer.

2.11 | Protein-protein interaction

GST pull-down: The gene encoding TRPC3-N (1–369aa) and TRPC3-C (659–836aa) was synthesized by Detai Biologics Co., Ltd. HEK 293-T cells were transfected with the above expression constructs to produce and purify recombinant protein for validating an interaction between TRPC3 and SIRT1 by bio-layer interferometry (BLI).

Co-immunoprecipitation (Co-IP): Cells or cells transfected with indicated vectors were solubilized in cell lysis buffer for IP (Beyotime, China) with proteases and phosphatase inhibitors (pH 7.4). Pre-cleared cell lysates were incubated with equal amounts of primary antibodies (2-5 μL) or IgG at 4°C before performing the pull-down with 50 μL of 1:1 Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, sc-2003) for 2 hours. Beads were washed four times with lysis buffer, boiled and elution collected for WB analysis.18,19

2.12 | Kinetic binding analysis by BLI

BLI experiments were performed using an Octet K2 system (Pall ForteBio Corp). Recombinant SIRT1 was immobilized on the Anti-Penta-HIS (HIS1K) Biosensors (ForteBio, part no. 18-5120) using black polypropylene microplates (Greiner Bio-One part no. 655209). Different concentrations of the TRPC3-C or -N peptide were applied in the mobile phase, and the association between the immobilized and flowing proteins was detected. The reference buffer was PBST and 5% DMSO (pH 7.4 PBS, tween 20 0.05% and 5% DMSO v/v). Statistical analysis was performed using Data Analysis 9.0 software. The dissociation rate constant (K_d) was obtained by curve fitting of the association and dissociation phases of the sensograms.

2.13 | Protein isolation and Western blot

Protein was extracted from heart tissues using a Tissue Homogenizer (PD500-TP12) (Prima, GBR) with RIPA Lysis and Extraction Buffer and protease inhibitor (Thermo Fisher Scientific). Protein concentrations were measured using a BCA protein assay kit (Bio-Rad), and 6%-8% SDS-polyacrylamide gel electrophoresis (PAGE) was applied to separate high-molecular-weight proteins (Solarbio, China). Col-I antibodies were purchased from Abcam (Col-I-αb6308). TRPC3, SIRT1 and TGF-β antibodies were purchased from CST (Cell Signalling Technology; TRPC3-77934, SIRT1-8469, and TGF-β-3711). The GAPDH antibody was obtained from Proteintech (GAPDH-60004-1-Ig). Primary antibodies (1:500) were incubated overnight with 5% bovine serum albumin at 4°C, and secondary antibodies (HRP-conjugated, 1:5000) were incubated for 60 minutes with TBST at room temperature. Proteins were detected with WESTAR ETA C ULTRA 2.0 (Cyanagen, ITA), and images were evaluated using a ChemiDoc MP imaging system (Bio-Rad).

2.14 | Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR)

Heart tissues were stored in Allprotect Tissue Reagent (Qiagen) for RT-qPCR. Total RNA was isolated from heart tissue ground over liquid nitrogen and extracted using the standard TRIzol method (Invitrogen, MA). cDNA was synthesized with 2 μg of RNA using the PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara Biomedical Technology). Primers for TRPC3, SIRT1, TGF-β, Col-I and GAPDH were obtained from Sangon Biotech. RT-qPCR was performed using SYBR® Premix Ex Taq™ (Tli RNaseH Plus) (Takara Biomedical Technology) under the following conditions, step one: 95°C for 5 minutes, 95°C for 10 seconds (reverse transcription); step two: 40 cycles of 95°C for 5 seconds and 60°C for 15 seconds (PCR); step three: dissociation protocol. Each cycle threshold (CT) value was normalized to the CT value of GAPDH. Fold changes were calculated with 2^(-ΔΔCT) compared to the control group. Specific primers were designed to amplify SIRT1 (SIRT1-F: 5′ TGTGGTGAAGATCTATGGAGGC 3′ and SIRT1-R: 5′ TGTACTTGCTGCAGACGTGGTA 3′), TRPC3 (TRPC3-F: 5′ CAGTGATGCGAGAAGGGT 3′ and 5′-CCTAAGGTTAAGTCGCCCTCG-3′).
TRPC3-R: 5′ CGTAGGCGTAGAAGTCGTCG 3′) and TGF-β (TGF-β-F: 5′-CCACCTGCAAGACCATCGAC 3′ and TGF-β-R: 5′-CTGGCGAGCCTTAGTTTGGAC 3′). All data were normalized to the mRNA levels of the housekeeping gene GAPDH (GAPDH-F: 5′ GGTTGTCTCCTGCGACTTCA 3′ and GAPDH-R: 5′ TGGTCCAGGGTTTCTTACTCC 3′).

**FIGURE 1** (Continues)
2.15 | Statistical analysis

Continuous variables are shown as the mean ± standard deviation. Data were evaluated for normal distribution by the Kolmogorov-Smirnov test, and homogeneity of variance was assessed by Levene’s test. An unpaired Student’s t-test was applied to compare normally distributed variables. Variables with non-normal distribution were compared with the Wilcoxon rank sum test. Fisher’s exact test was used to estimate categorical variables. When the variance was not homogeneous, the Tukey test was applied to test the means of multiple samples. Multiple t-tests were performed for multiple-group comparisons. Student t-tests were used to compare only two groups.

3 | RESULTS

3.1 | Patients with AF are more often diagnosed with severe cardiac fibrosis in the atrium than SR patients

As shown in Figure 1A-C, the left atrial appendage of AF patients exhibited an increase in TRPC3 and pro-fibrotic proteins, such as...
FIGURE 2 (Continues)
TGF-β and Col-I. This was accompanied by a down-regulation of SIRT1, which was detected at both the protein and mRNA levels. Figure 1D shows that patients with AF more often presented with atrial fibrosis compared to patients with SR, as detected by IHC and Masson staining experiments. In addition, we observed by electron microscopy that the ultra-structure of atrial tissues was severely damaged in AF patients compared with SR patients (Figure 1E). For example, the fascicle was ruptured, the crude and fine filaments were loosely arranged, and the mitochondria displayed compensatory enlargement, hyperplasia and disordered crista. The baseline characteristics of AF and SR patients are presented in Table 1, which shows that the morbidity of hyperhomocysteinemia and the QTc prolongation in AF patients exceeded that in SR patients. On the other hand, the incidence of hypertension was similar in AF and SR patients. Intriguingly, the phenomenon of AF combined with HF was commonly observed, accounting for 33.3% of patients with AF, which is consistent with the current statistics of this comorbidity.

3.2 Development of HFP EF in high-Hcy fed mice with TAC

Figure 2A shows how the Hcy diet was administered to transverse aortic constriction (TAC) mice (n = 25) at 4-16 weeks. TAC mice that went through sham surgery and were fed a normal diet were considered the sham (SH) group (n = 10). Repeat echocardiogram (ECG) was performed at 16 and 18 weeks of age. We performed programmed ECG analysis, RT-qPCR and Western blot in the three groups at 18 weeks of age. B1, The value of ejection fraction (EF) in SH, NH and HH mice. B2, The value of interventricular septum thickness (IVS-S). B3, B4, Baseline E (early filling)/A (atrial filling) and E/E’ ratios amongst the three groups. B5, The value of left ventricular internal diastolic diameter (LVIDd). C, Representative images from pulsed-wave Doppler showing E and A wave. D, Representative M-mode images of the three groups. Error line indicates mean and standard deviation. *P < .01 and **P < .001. Mixed model regression with post hoc testing (Tukey adjustment) was used for 2B.
| Weeks | SH      | NH      | HH      |
|-------|---------|---------|---------|
|       | 4       | 7       | 16      | 4       | 7       | 16      | 4       | 7       | 16      |
| N     | 10      | 9       | 9       | 25      | 21      | 18      | 25      | 22      | 17      |
| Heart rate | 489 ± 32 | 475 ± 26 | 447 ± 38 | 458 ± 30 | 451 ± 29 | 439 ± 27 | 453 ± 36 | 479 ± 33 | 451 ± 37 |
| E wave | 331.8 ± 36.95 | 345.5 ± 19.31 | 339.2 ± 27.95 | 358.9 ± 13.59 | 320.4 ± 17.41 | 300.9 ± 30.21 | 355.4 ± 10.54 | 313.4 ± 18.41 | 280.2 ± 34.72 |
| E' wave | 374.4 ± 7.48 | 35.48 ± 6.48 | 30.84 ± 6.077 | 38.74 ± 10.77 | 20.57 ± 3.54 | 15.94 ± 3.838 | 37.70 ± 8.015 | 19.23 ± 2.87 | 13.17 ± 2.660 |
| A wave | 194.9 ± 29.31 | 201.2 ± 23.26 | 200.6 ± 21.668 | 211.5 ± 20.54 | 249.9 ± 21.12 | 250.6 ± 29.26 | 197.0 ± 20.65 | 234.5 ± 21.13 | 257.3 ± 42.35 |
| EF%   | 67.5 ± 11.2 | 64.0 ± 4.6 | 60.7 ± 6.1 | 57.3 ± 9.2 | 57.7 ± 9.7 | 60.0 ± 5.9 | 60.4 ± 11.9 | 55.6 ± 7.7 | 59.0 ± 6.1 |
| FS%   | 41.5 ± 3.5 | 39.7 ± 3.0 | 42.8 ± 2.1 | 39.7 ± 1.6 | 45.3 ± 2.4 | 38.7 ± 4.2 | 39.6 ± 3.8 | 43.2 ± 4.7 | 37.4 ± 2.9 |
| LVIDd, mm | 3.148 ± 0.176 | 3.082 ± 0.245 | 3.064 ± 0.174 | 3.026 ± 0.200 | 3.488 ± 0.214 | 3.943 ± 0.320 | 3.188 ± 0.220 | 3.583 ± 0.187 | 4.256 ± 0.362 |
| LVIDs, mm | 2.03 ± 0.19 | 1.78 ± 0.34 | 2.12 ± 0.09 | 1.58 ± 0.28 | 2.62 ± 0.26 | 3.31 ± 0.39 | 1.76 ± 0.41 | 2.47 ± 0.15 | 3.23 ± 0.21 |
| PWTd, mm | 0.59 ± 0.09 | 0.89 ± 0.15 | 0.99 ± 0.12 | 0.67 ± 0.10 | 0.79 ± 0.18 | 0.93 ± 0.11 | 0.71 ± 0.18 | 0.85 ± 0.06 | 1.21 ± 0.21 |
| PWTs, mm | 0.78 ± 0.12 | 0.89 ± 0.17 | 1.03 ± 0.09 | 0.83 ± 0.23 | 0.94 ± 0.19 | 1.27 ± 0.14 | 0.87 ± 0.11 | 1.09 ± 0.16 | 1.43 ± 0.34 |
| BNP, pg/mL | 48 ± 6 | 224 ± 28 | 293 ± 47 | 0.45 ± 0.054 | 0.56 ± 0.11 | 0.63 ± 0.10 |

Note: Heart rate, echocardiography parameters, BNP and heart weight of mice. Values are presented as mean ± SEM. EF% and FS%, ejection fraction % and fractional shorting %; LVIDd and LVIDs, left ventricular internal diameter at end-diastole (d) and at systole (s); PWTd and PWTs, the posterior wall thickness at end-diastole (d) and end-systole (s); BNP, type B natriuretic peptide.
received the high-Hcy diet were classed as the HH group and those that received a normal diet as the NH group, with mice undergoing sham surgery regarded as the SH group. To induce AF, we administered a constant dose of acetylcholine (0.5 μL/mg), which was injected into each mouse through the caudal vein. Figure 2B-E reveals echocardiographic results at 4, 7 and 16 weeks of age. The EF was not significantly different at baseline (4 weeks) amongst the three groups (Figure 2B). The interventricular septal thickness (IVS-S) in HH mice was markedly greater than that in the NH mice at 16 weeks of age (1.914 ± 0.167 in HH vs 1.832 ± 0.134 in NH, $P < .001$; Figure 2B). The

![Figure 2B](image1)

![Figure 2C](image2)

![Figure 2D](image3)

![Figure 2E](image4)

**FIGURE 3** Programmed acetylcholine stimulation (PES) and ECG analyses in SH, NH and HH mice. A, Normal SR was typically observed in the ECGs of the SH group (n = 7/9), and the speed was 125 ms. B, ECGs indicating AF were frequently observed in the HH group (n = 10/17). C, Ventricular fibrillation (VF) was observed in the NH (n = 3/18) and HH (n = 4/17) groups. D, Increased susceptibility to AF in the HH group (N = 10/17) than in the NH group (N = 8/18), with the lowest susceptibility in the SH group (N = 2/9). E, The duration of AF in the three groups. F, The value of heart weight-to-body weight (HW/BW). G, The heart weight-to-tibia length ratio (HW/TL). H, Representative Masson staining showed transverse section in atria. I, Representative Masson staining images with magnified local images in atrial tissues. J, Survival rate of the three groups over different time periods. K, Results are represented as cardiac sizes in the three groups. *$P < .05$, **$P < .01$. Mixed model regression with post hoc testing (Tukey adjustment) was used in 3F, 3G, and Fisher’s exact test was used in 3D.
FIGURE 3 (Continued)
FIGURE 4 (Continues)
FIGURE 4 (Continues)
FIGURE 4 (Continues)
results confirmed that baseline E/A ratios were not different amongst SH, NH and HH mice at 4 weeks of age before TAC surgery, whereas the E/A ratio was decreased in HH mice compared with the NH mice at 16 weeks, although no statistically significant results were observed at 7 weeks (1.288 ± 0.085 in NH vs 1.255 ± 0.128 in HH, P > .05; Figure 2B), with greater significant differences in the values amongst the NH and HH groups (1.099 ± 0.101 in HH and vs 1.205 ± 0.083 in NH, P < .001; Figure 2B), indicating impaired diastolic function. The ratio of transmural flow velocity to annular velocity (E/E′) is a non-invasive parameter for left ventricular (LV) stiffness.20 There was a slight variability in the E/E′ ratio at the baseline at 4 weeks, and the value of E/E′ was increased in HH mice beyond that in the NH mice at 16 weeks (21.89 ± 3.738 in HH vs 19.53 ± 3.206 in NH, P < .001 at 16 weeks but 16.82 ± 2.495 in HH vs 15.97 ± 2.513 in NH, P > .05 at 7 weeks; Figure 2B). The measurements of LVIdd were markedly increased following TAC (NH and HH) was observed, especially in the HH group (Figure 2B, Table 3). Evolving mitral flow velocity patterns were analysed during different time periods (Figure 2C). The ultrasonic images at different periods were obtained from a longitudinal section of the heart (Figure 2D). In addition, increasing posterior wall thickness at end-diastole (PWTd) and posterior wall thickness at end-systole (PWTs) measurements were concurrently noted (Table 3). However, the heart rate (reported here as the RR interval) was not different amongst the three groups (Table 3).

### 3.3 Arrhythmia induced by acetylcholine and atrial fibrosis in mice

Figure 3A-C shows the results of ECGs recorded in the three groups within five minutes of acetylcholine injection. Normal SR was typically observed in the ECGs of the SH group (n = 7/9), and the mean speed was 125 ms (Figure 3A). ECGs indicating AF include the following three characteristics: irregular small F waves, no P wave and an unequal RR interval and were frequently observed in the HH group (n = 10/17) (Figure 3B). In addition, the features of ventricular fibrillation (VF) include the disappearance of the QRS wave, which is replaced by different VF waves and were observed in the NH (n = 3/18) and HH (n = 4/17) groups (Figure 3C,D). Figure 3D illustrates that AF was induced in 10 out of 17 (58.8%) mice in the HH group; the frequency of AF was higher in the HH group than in the NH group [8 of 18 (44.4%)], but the difference was not statistically significant. However, both the HH and NH groups exhibited significantly higher induction ratios of AF than the SH group that did not undergo TAC [2 of 9 (22.2%)] (P < .01). VF was not observed in the SH mice, but nonmonorphic VF was observed in the NH [3 of 18 (16.7%)] and HH [4 of 17 (23.5%)] groups (Figure 3D). Despite the lack of statistical significance, the propensity to develop AF with or without feeding a high-Hcy diet was higher in groups that underwent TAC (HH and NH groups) than in the SH group (Figure 3D). Interestingly, the duration of induced AF was longer in both the HH and NH groups than in the SH group, especially in the HH group (Figure 3E).

Next, we studied whether Hcy affects the process of atrial fibrosis in animal experiments. There was a slight fluctuation in the heart weight/body weight ratio (HW/BW) at the baseline at 4 weeks, and the value of HW/BW was increased in HH mice beyond that in the NH mice at 16 weeks (6.552 ± 0.418 in HH vs 5.795 ± 0.461 in NH, P < .001 at 16 weeks but 4.777 ± 0.610 in HH vs 4.679 ± 0.479 in NH, P > .05 at 7 weeks; Figure 3F). The similar changes were observed for the heart weight-to-tibia length ratio (HW/TL) at 16 weeks of age (Figure 3G). In addition, Masson's trichrome staining simultaneously affirmed that the HH groups were more vulnerable to fibrosis, compared with the NH group (Figure 3I). Moreover, transverse sections of atrium and cardiac size showed a greater enlargement in the HH group, compared with the NH group (Figure 3H,K) and further demonstrated that Hcy could exaggerate the adverse influence of TAC-induced HF. Survival analysis showed that mice in the NH and HH groups exhibited higher mortality, especially after 10 weeks, than that in the SH group, as shown in Figure 3J.

### 3.4 SIRT1-overexpression and TRPC3-KD mice can efficiently control Hcy-mediated atrial fibrosis

Figure 4A shows the procedure for intravenously injecting purified SIRT1-overexpression (SIRT1-OE) or TRPC3-shRNA lentivirus through the tail vein of mice at one week of age, respectively regarded as SIRT1-OE or TRPC3-knockdown (TRPC3-KD) mice. Scramble lentivirus was injected into vector mice as a negative control. At 4 weeks, we performed the TAC operation and fed mice with a high-Hcy diet for 10 weeks. Next, echocardiography was used to detect the EF and other indicators at 7 and 16 weeks. Figure 4B-C shows that the degree of fibrosis was increased in the HH+vector group compared with the NH+vector group (Figure 4). Interestingly, when TAC mice were fed a high-Hcy diet, the HW/TL ratio was lower in the TRPC3-KD or SIRT1-OE mice, which indicates significant suppression of the extent of atrial fibrosis compared to the HH+vector mice (Figure 4), as well as those mice fed with a normal diet (Figure 4). Although it was showed a slight increase in the level of atrial fibrosis in the TRPC3-KD or SIRT1-OE mice...
FIGURE 5 (Continues)
with a high-Hcy diet compared to those mice with a normal diet, there is no statistic significance (Figure 4). According to their echocardiography, the IVS-S at end-systole and LVIDd were efficiently alleviated by the above treatments (Figure S1A). Meanwhile, the Masson staining of TRPC3-KD+HH and SIRT1-OE+HH mice were dramatically decreased in comparison with the HH+vector mice (Figure 4C), whilst the EF level

FIGURE 5 Hcy modulates the expression of TRPC3 protein and affects the activity of SIRT1. A, B, The expression levels of TRPC3, SIRT1, TGF-β and Col-I in mouse atrial fibroblast under different concentrations of Hcy or different treatments. C, D, The protein levels of TRPC3, SIRT1 and TGF-β in TRPC3-shRNA-transfected stable cell lines with or without Hcy stimulation. E, F, The expression levels of TRPC3, SIRT1, TGF-β and Col-I in TRPC3-OE or SIRT1-OE stable cell lines. G, H, The promotion of fibroblast proliferation was detected by CCK-8. Error line indicates mean and standard deviation. *P < .05 and **P < .01 vs scramble; #P < .05, ##P < .01 vs (500 μmol/L) Hcy group. Unpaired t-test was used for 5A–5F, and mixed model regression with post hoc testing (Tukey adjustment) was used for 5G, 5H.
**FIGURE 6** (Continues)
remained at a relatively stable state (Figure S1B). In addition, transgenic mice displayed no apparent changes in cardiac structure and function (Figure S1C,D). This result confirmed that despite the influence of the high-Hcy diet and the TAC surgery, the protein level of TRPC3 and the related TGF-β signalling pathway were inhibited in the TRPC3-KD+HH group, whilst SIRT1 was increased. Similar results were observed in the SIRT1-OE+HH group with the lower level of TGF-β (Figure 4D). In general, the TRPC3-KD and SIRT1-OE models generated by injecting purified lentiviruses exhibited dramatically abrogated Hcy-induced fibrosis in atrial fibroblasts and decreased levels of pro-fibrotic proteins, such as TGF-β and Col-I (P < .001). Figure 4E shows the procedure for intraperitoneal injection of Res 20 mg/kg/d for 21 days from the fourth week, whilst another group were fed a diet containing folic acid and injected with the same dose of saline, respectively regarded as H+Res or HH+FC mice. Interestingly, regardless of whether folic acid and vitamins were added to the food or not, there was no notable protection from the damage caused by high Hcy levels (Figure 4F,H). However, Res attenuated the enhancement of TRPC3 and decrease in SIRT1 induced by the high-Hcy diet combined with TAC injury and controlled the TGF-β improvement (Figure 4F,H). In addition, the mRNA levels of TRPC3 and SIRT1 in the above groups were consistent with their protein levels (Figure 4I).

3.5 Hcy can promote the proliferation and differentiation of atrial fibroblasts and modulate the relevant protein levels

First, the results revealed that the expression levels of total TRPC3 were significantly increased by the intervention of Hcy in a dose-dependent manner (Figure 5A), compared with those in the control group (Hcy 0 μmol/L). However, those expression levels were significantly decreased by Pyr-10 treatment, which is characterized by the inhibition of DAG-mediated TRPC3 signalling pathway (P < .001, Figure 5B). These results further confirmed that Hcy could activate the upstream protein of DAG, GPCRs and increase cardiac TRPC3 expression in mouse atrial fibroblast, and that effect was abolished by Pyr-10. Second, we observed that the protective effects of SIRT1 against cardiac remodelling were decreased by Hcy (P < .001). Intriguingly, Res could prevent the Hcy-induced enhancement of TRPC3 level. In addition, the above effects of Hcy on atrial fibroblast were accompanied by a reduction in the expression level of fibrotic proteins, such as TGF-β, which was demonstrated to be a pivotal molecule in fibrosis (P < .001) (Figure 5B). Finally, when the inhibitor of SIRT1 (Sal) was applied to mice fed a high-Hcy diet, the pro-fibrotic effects on atrial fibroblast were exacerbated (Figure 5B).

Second, we examined the expression levels of cardiac TRPC3 using purified lentivirus to transfect primary cultured atrial fibroblast. Figure S2A shows the fluorescence intensity when the multiplicity of infection (MOI) value was 1, 5, 10 and 20. Of note, the transfection efficiency was highest at 20 MOI. Cell viability was not significantly affected by lentivirus transfection with or without Hcy stimulation (Figure S2B). We also detected the protein level of TRPC3 and SIRT1. It exhibited a relatively stable state in the expression level of SIRT1 and TGF-β, Col-I in TRPC3-shRNA cell lines, even under different concentrations of Hcy stimulation (Figure 5C). Moreover, regardless of the transfection of TRPC3-shRNA or SIRT1-OE lentivirus, the protein levels of SIRT1 increased as the MOI value increased; the level of TRPC3 decreased in cells transfected by TRPC3-shRNA (Figure 5D), but not in cells transfected by SIRT1-OE lentivirus (Figure 5E). It is worth emphasizing that the protein level of TGF-β was decreased, even though the level of TRPC3 was not markedly changed in SIRT1-OE stable cell lines (Figure 5E). On the other hand, transfection of TRPC3-OE plasmids into HEK293 cells elicited the overexpression of TRPC3 protein as well as the suppression of endogenous SIRT1 protein levels in a dose-dependent manner along with the promotion of TGF-β expression (Figure 5F), which suggested that TRPC3 can affect the transcription and translation of SIRT1, which further modulates the protein levels of TGF-β. Finally, the results suggest that Hcy could promote the proliferation and differentiation of fibroblasts (Figure 5G). In contrast, the promotion of fibroblast proliferation by Hcy was blocked in TRPC3-shRNA stable cell lines (Figure 5H).

3.6 SIRT1 is an TRPC3-interacting partner

Although TRPC3 is well-established to play a central role in transducing cardiac fibrosis signalling, the mechanisms underlying its signal transduction function remain poorly understood. To address this issue, researchers have identified SIRT1 as a modulator of the transcription of TGF-β-dependent genes, which participate in the process of fibrosis. In a preliminary experiment, we found that Hcy could increase the level of TRPC3; nevertheless, the protein level of SIRT1 was decreased (Figure 5A). SIRT1 could be a potential TRPC3-interacting partner, as both regulate the process of cardiac fibrosis in synergy. To confirm this hypothesis, we performed an in vitro GST pull-down assay using Flag-TRPC3 expressed in HEK293T cells and purified GST-TRPC3 to further validate the TRPC3-SIRT1 interaction in mammalian cells. In addition, IP experiments were performed to corroborate that Flag-TRPC3 and HA-SIRT1 interact in HEK293T cells (Figure 6B). Endogenous TRPC3 protein immunoprecipitated
with a SIRT1 antibody (Figure 6C), indicating that TRPC3 and SIRT1 could form a protein complex in cells. Moreover, the interaction between endogenous TRPC3 and SIRT1 was markedly improved by Hcy stimulation (Figure 6D). Finally, IF staining showed that TRPC3 and SIRT1 co-localized in the cytoplasm of cells (Figure 6A), suggesting that the binding of these proteins occurs in the cytoplasm. Next, we determined the functional outcomes of the TRPC3-SIRT1 interaction and evaluated whether TRPC3 affects the functions of SIRT1. We demonstrated that the regulation of fibrosis by SIRT1 and TRPC3 is antagonistic. We found that the stable cell line transfected with TRPC3-OE lentivirus exhibited a low expression level of SIRT1 (Figure 5F), which suggested that TRPC3 is required for the activation and translocation of TGF-β into the nucleus of fibroblasts by mediating the trafficking and activity of SIRT1.

Moreover, BLI results were used to evaluate the direct interaction between full-length SIRT1 and different binding fragments of TRPC3. TRPC3 contains three main domains, including extracellular, transmembrane and cytoplasmic N-terminal (1-369aa) or C-terminal (659-836aa) (Figure 6E). The intensity of the binding affinity between purified protein of TRPC3-C and SIRT1 increased with various concentrations of TRPC3-C (180.6, 365.1, 730.3, 1461 and 2921 μmol/L) in a dose-dependent manner (Figure 6G,H). The values were presented as, $K_{on} = 500 \pm 19.42 \text{ M}^{-1} \text{ S}^{-1}$ for the association phase, $K_{dis} = (6.46 \pm 0.15) \times 10^{-5} \text{ S}^{-1}$ for the dissociation phase and $K_D = (6.29 \pm 0.038) \times 10^{-8} \text{ M}$. However, the binding of SIRT1 and TRPC3-N was not existed, even if it had given different concentrations of TRPC3-N to response with SIRT1 peptide (140.2, 280.4, 560.8, 1122, 2243 μmol/L). The curve was declined rather than ascended in the association. The values were $K_{on} = 6.43 \pm 0.046 \text{ M}^{-1} \text{ S}^{-1}$ for the association phase, $K_{dis} = (6.28 \pm 0.72) \times 10^{23} \text{ S}^{-1}$ for the dissociation phase and $K_D = (9.27 \pm 0.039) \times 10^{21} \text{ M}$ (Figure 6H). In addition, this result was further verified in mammalian cells transfected with the plasmids encoding the C-tail of TRPC3 and full-length SIRT1 (Figure 6F).

4 | DISCUSSION

With the increasing prevalence of cardiac structure remodelling in various cardiovascular diseases, the pathogenesis of cardiac fibrosis is an important research topic. Here, we used hyperhomocysteinemia to aggravate the progression of atrial fibrosis and ultimately the structural re-entry circuits and local conduction block in the atrium. It indirectly determines the basic pathogeny of AF. We found that patients with AF were more vulnerable to severe atrial fibrosis, than SR patients (Figure 1E, Table 1). Meanwhile, AF patients requiring cardiothoracic surgery were also more likely to develop hyperhomocysteinemia and HF as comorbidity (Table 1). TAC has proven to be a relatively reliable technique for generating HF models.23-25 In our study, TAC was performed at 4 weeks of age to establish HF models, which develop cardiac fibrosis; these mice were also fed a high-Hcy diet for 12-14 weeks to exacerbate the extent of cardiac fibrosis, which further demonstrated that Hcy exaggerates cardiac remodelling. As it is difficult to substantiate the spontaneous development of AF in mice, we applied acetylcholine in our experimental model, in order to observe the susceptibility of inducing arrhythmias by atrial fibrosis. This revealed that TAC mice with a high-Hcy diet increased the prevalence of AF compared to the NH mice, which we could confirm within 2 minutes of administering the injection of acetylcholine. A high Hcy diet alone may not cause cardiac structural changes in mice. For this reason, we used TAC to establish the model of HFrEF, which means that not only could we observe the relationship between cardiac fibrosis and a high Hcy diet in our HF model, but we could also detect the susceptibility of AF to Hcy stimulation. The increase in the incidence and duration of AF may be correlated with the extent of myocardial fibrosis in the TAC model.26,27 At the same time, there was likely a tendency to develop atrial fibrosis in the TAC animal models. Moreover, a greater degree of fibrosis was observed in HH mice than in the NH mice (Figure 3I). This AF occurrence was due to interruption of the continuity of atrial myocytes by excessive extracellular matrix (ECM) deposition and the formation of aberrant electrical circuits, which assisted in understanding the disorder of current conduction in AF (Figure 3B). In our model, the duration of AF was more easily prolonged in the HH group than in the NH group, which further demonstrated that Hcy is a risk factor for atrial fibrosis-related AF and the increasing risk of AF.28,29 Amongst the
treatment groups, HF mice were found to manifest cachexia with different degree of death, which is characterized by a reduction in subcutaneous fat, activity and food intake, starting from 7 weeks of age.30

TRPC3 is considered an indispensable factor in regulating the mechanisms of fibrosis development in mouse cardiomyocytes. The expression level of this channel was higher in the left atrial appendage of AF patients than in SR patients and accompanied by enhanced expression of the pro-fibrosis protein, TGF-β. Concurrently, we found similar results in the animal models; higher expression levels of TRPC3 and TGF-β were observed in the HH mice, compared with in the NH mice. Previous study demonstrated that Hcy can bind to GPCRs, as the largest of cell-surface receptors and exacerbate the process of cardiac fibrosis.31 In addition, TRPC3 activity is directly regulated by PKC phosphorylation, which is depended on GPCR activation. In general, GPCRs degradation initiates PLC activity that leads to production of DAG and subsequently affect PKC function. Combined with the evidence of increased expression levels of TRPC3 in Hcy group, we speculated that Hcy could trigger the mechanism of atrial fibrosis via TRPC3, depending on the activation of GPCRs signalling pathway. Although the effect of added dietary folic acid and vitamins was not as notable as that achieved by directly inhibiting the TRPC3 or up-regulating the SIRT1 gene in HH mice, such dietary intervention may serve as a potential therapy for homocysteinemia patients with HF. Second, in our cell model, high-Hcy conditions elicited the up-regulation of TRPC3 protein and the pro-fibrotic modulator TGF-β in a dose-dependent manner, thereby enhancing the proliferation and differentiation of fibroblasts.

We explored whether inhibition of TRPC3 could attenuate the fibrotic response of cardiomyocytes induced by Hcy. Previous studies using TRPC3-deficient (TRPC3−−) mice or a pharmacological inhibitor of TRPC3, Pyr-3, revealed that TRPC3 participated in mechanical stress-induced LV diastolic dysfunction in mice.32 Previous research has shown that TAC significantly increased myocardial cell size in both TRPC3+/− and TRPC3−− mice. On the other hand, analysis of collagen deposition demonstrated a marked decrease in fibrosis in TRPC3−/− mouse hearts compared with TRPC3+/− mouse hearts.33 As interstitial fibrosis is perceived to be a major cause of cardiac remodelling, we assessed whether suppression of TRPC3 could attenuate Hcy-induced interstitial fibrosis in cardiac myocytes. The experimental results showed that the protein level of the fibrotic gene, TGF-β, was significantly suppressed in the TRPC3-KD+HH mice, compared with the HH+vector mouse (Figure 4A-D). Next, we take atrial mouse fibroblasts as the cell model. Pyr-10, an selective inhibitor of TRPC3, could markedly block the DAG-mediated TRPC3 signalling pathway, controlling the extent of fibrosis in the cell model.32,34. In our study, it was observed the lower protein levels of TRPC3 and TGF-β, in Hcy+Pyr-10 group, compared to Hcy group, which implied that Pyr-10 abolished the effect of Hcy-mediated atrial fibrosis via the inhibition of DAG-TRPC3 signalling pathway. Moreover, it was attenuated Hcy-induced atrial fibrosis (Figure 5B,D) and reduced the proliferation of fibroblasts in TRPC3-shRNA-transfected fibroblasts (Figure 5H). These results indicated that TRPC3 is critical mediator in the TGF-β signalling pathway and predominantly mediates Hcy-induced maladaptive fibrosis in mouse hearts. Although TGF-β signalling is an important role for cardiac remodelling,35 the role of TRPC3 in regulating TGF-β and promoting fibrosis remains unknown.

We further studied the potential molecular mechanisms underlying how TRPC3 modulates TGF-β-mediated cardiac fibrosis. It is worth acknowledging that up-regulation of SIRT1, an important cytokine that protects against cardiac remodelling was observed and led to the inhibition of collagen accumulation by inhibiting TGF-β expression.36,37 The severity of cardiac fibrosis was correlated with a lower expression level of SIRT1 in AF patients and HH mice. However, adding Res, an activator of SIRT1, could effectively attenuate cardiac fibrosis in both animal and cell models (Figure 4H). Similarly, SIRT1-OE+HH mice efficiently mitigated the extent of atrial fibrosis compared with that in the HH+vector group (Figure 4A-D). Thus, SIRT1 may play a pivotal role in the mechanism of cardiac fibrosis.

Interestingly, SIRT1 overexpression inhibited the TGF-β excess induction, but no changes were not observed in the protein level of TRPC3 (Figure 5E). In addition, with the increase of TRPC3 by titrating the amount of ectopic Flag-TRPC3, SIRT1 protein levels were significantly decreased in a dose-dependent manner, following the enhancement of TGF-β (Figure 5F), which suggested that SIRT1 might be required for the indirect adjustment of TGF-β expression mediated by TRPC3. Indeed, the application of the SIRT1 inhibitor, Salermide, to atrial fibroblasts further enhanced the protein level of TGF-β and Col-I, but no change in the expression levels of TRPC3, compared with HH groups (Figure 5B). In our study, it was identified SIRT1 as a novel regulator and partner of TRPC3 via direct or indirect binding. Although previous studies have shown that both SIRT1 and TRPC3 participate in mediating TGF-β signalling.32,38,39 it remains unknown how TRPC3 regulates the localization of SIRT1 and whether these proteins directly interact with each other. In fibroblasts transfected with purified TRPC3-shRNA lentiviruses, the expression levels of SIRT1 are increased with the MOI value in a dose-dependent manner, which indicates that the stability of SIRT1 is directly affected by TRPC3. Conversely, transfection of the SIRT1-OE vector into HEK293 cells did not affect the protein expression level of TRPC3 compared to transfection of a scrambled vector (Figure 5E). Additionally, the co-IP, BLI and IF results demonstrated the correlation between TRPC3 and SIRT1 in regulating the process of fibrosis (Figure 6A-D), and moreover, it affirmed their binding domains to the C-terminal (659-836aa) of TRPC3 and SIRT1 (Figure 6E-H). As further discussed below, TRPC3 can physically interact and subsequently activate SIRT1 in response to TGF-β signalling and play a prominent role in promoting the proliferation and differentiation of fibroblasts.

Recent studies have determined that SIRT1 can modulate the regulation of a variety of cellular processes associated with RAS. Amongst them, SIRT1 protects the cell from oxidative stress.40 Combined with the evidence of the interaction between TRPC3 and SIRT1, it indicated that Hcy activates TRPC3-SIRT1 axis by modulating TGF-β activation, driving fibrosis in both cardiomyocytes and
cardiac fibroblasts. In this study, we investigated the mechanism of TRPC3 in the progression of atrial fibrosis both in vitro and in vivo. By analysing left atrial appendage specimens, we uncovered that TRPC3 levels were closely correlated with the degree of atrial fibrosis and the incidence of AF. Moreover, patients with hyperhomocysteinemia exhibited increased protein levels of TRPC3 and decreased levels of SIRT1 along with activation of the TGF-β signalling pathway (Figure 7). In agreement with this, our analysis showed that the RNA level of TRPC3 was increased in the AF group, whereas the RNA level of SIRT1 was reduced (Figure 1C) compared with that in the SR group. Remarkably, we further confirmed that the Hcy group exhibited a marked increase in fibroblast proliferation and enhanced expression of a pro-fibrotic protein, TGF-β, in vitro and in vivo. Interestingly, our experiments also revealed that TRPC3 can directly interact with SIRT1, acting as a negative modulator of SIRT1, leading to TGF-β signalling pathway activation under Hcy stimulation.

5 | CONCLUSIONS AND PERSPECTIVE

Our present study not only illustrates the biochemical function of TRPC3, which binds directly to SIRT1 through its C-terminal (659-836aa) to modulate TGF-β signalling, with the interaction intensified under Hcy stimulation, but also unveils the roles of TRPC3 and SIRT1 in atrial structure remodelling and fibrosis, which reciprocally increase the occurrence of AF accompanied by HF (Figure 7). Together, our results suggest that TRPC3 may serve as a biomarker for preventing the consequence of atrial fibrosis in AF patients with homocysteinemia, especially as activation of SIRT1 is associated with inhibition of the TGF-β signalling pathway. However, the underlying mechanisms of atrial fibrosis are mediated by TRPC3 and SIRT1 merits further investigation.

ACKNOWLEDGEMENTS

We are grateful to Dr Juxiang Li for careful reading and revision of the manuscript.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS

Lu Han and Juxiang Li designed the experiment and interpreted results. Yanhua Tang: contributed left atrial appendage specimens of AF or SR patients. Lu Han and Shaochuan Li: collected the data. Lu Han, Yanqing Wu, Qinghua Wu, Kui Hong and Xiaoshu Cheng: performed the research. Lu Han and Juxiang Li: analysed the data and wrote the paper. All authors have read and approved the final manuscript.

REFERENCES

1. Gnonlonfoun D, Adjien C, Gniamo R, et al. Ischemic stroke due to embolic heart diseases and associated factors in Benin hospital setting. J Neurol Sci. 2018;387:124-128.
2. Mansour M, Heist EK, Agarwal R, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. Am J Cardiol. 2018;121:1192-1199.
3. Nasso G, Bonifazi R, Romano V, et al. Increased plasma homocysteine predicts arrhythmia recurrence after minimally invasive epicardial ablation for nonvalvular atrial fibrillation. J Thorac Cardiovasc Surg. 2013;146:848-853.
4. Iguchi M, Tezuka Y, Ogawa H, et al. Incidence and risk factors of stroke or systemic embolism in patients with atrial fibrillation and heart failure—the Fushimi AF Registry. Circ J. 2018;82:1327-1335.
5. Luong C, Barnes ME, Tsang TS. Atrial fibrillation and heart failure: cause or effect? Curr Heart Fail Rep. 2014;11:463-470.
6. Zhao L, Wang W, Yang X. Anticoagulation in atrial fibrillation with heart failure. Heart Fail Rev. 2018;23:563-571.
7. Abdul-Rahim AH, Perez AC, MacIsaac RL, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and Preserve trials. Eur Heart J. 2017;38:742-750.
8. Mueller KAL, Heinzmann D, Klingel K, et al. Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 2017;69:2160-2172.
9. Vacek TP, Sen U, Tyagi N, et al. Homocysteine effects classical pathway of GPCR down regulation: Gq/11, G12/13, Gi/o. Mol Cell Biochem. 2009;321:1-8.
10. Numaga-Tomita T, Oda S, Shimauchi T, Nishimura A, Mangmool S, Nishida M. TRPC3 channels in cardiac fibrosis. Front Cardiovasc Med. 2017;4:56.
11. Li Q, Liu X, Wei J. Aging related perilostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescence. Biophys Res Commun. 2014;452:497-502.
12. Koz ST, Etem EO, Baydas G, et al. Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats. Brain Res. 2012;12:29-38.
13. Liu J, Rigel DF. Echocardiographic examination in mice and mice. Methods Mol Biol. 2009;573:139-155.
14. Gallet R, de Couto G, Simsolo E, et al. Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in mice by decreasing fibrosis and inflammation. JACC Basic Transl Sci. 2016;1:14-28.

15. Takemoto Y, Slough DP, Meinek G, et al. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule. FASEB J. 2018;32:1778-1793.

16. Song L, Wang L, Li F, et al. Bone marrow-derived tenasin-C attenuates cardiac hypertrophy by controlling inflammation. J Am Coll Cardiol. 2017;70:1601-1615.

17. Shao J, Xu L, Chen L, et al. Arf13b promotes gastric tumorigenesis by regulating Snf2b trafficking and activation of the Hedgehog signaling pathway. Cancer Res. 2017;77:4000-4013.

18. Guerrera D, Shah J, Vasileva E, et al. PLEKH7 recruits PDZD11 to adherens junctions to stabilize nectins. J Biol Chem. 2016;291:11016-11029.

19. Shi C, Huang X, Zhang B, et al. The inhibition of heat shock protein 90 facilitates the degradation of poly-alanine expanded poly (A) binding protein nuclear 1 via the carboxyl terminus of heat shock protein 70-interacting protein. PLoS ONE. 2015;10:e0138936.

20. Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation. 2007;116:637-647.

21. García-Vizcaino EM, Liarte S, Alonso-Romero JL, Nicolás FJ. Sirt1 interaction with active Smad2 modulates transforming growth factor-β regulated transcription. Cell Commun Signal. 2017;15:50.

22. Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The role of sirtuins in antioxidant and redox signaling. Antioxid. Redox Signal. 2018;28(8):643-661.

23. Methawasin M, Strom JG, Slater RE, Fernandez V, Saripalli C, Granzier H. Experimentally increasing the compliance of titin counteracts ventricular arrhythmias in rats with heart failure and preserved ejection fraction. J Cell Mol Med. 2018;22:4118-4133.

24. Sheng JJ, Feng HZ, Pinto JR, Wei H, Jin JP. Increases of desmin and α-actinin in mouse cardiac myofibrils as a response to diastolic dysfunction. J Mol Cell Cardiol. 2016;99:218-229.

25. Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol. 2007;50:359-367.

26. Kondo H, Abe I, Fukui A, et al. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation. J Cardiof. 2018;71:310-319.

27. Cho JH, Kilfoil PJ, Zhang R, et al. Delayed repolarization underlies ventricular arrhythmias in rats with heart failure and preserved ejection fraction. Circulation. 2017;136:2037-2050.

28. Yao Y, Shang MS, Dong JZ, Ma CS. Homocysteine in non-valvular atrial fibrillation: role and clinical implications. Clin Chim Acta. 2017;475:85-90.

29. Yao Y, Shang M-S, Gao L-J, et al. Elevated homocysteine increases the risk of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation with low CHA2DS2-VASc score. Europace. 2017;20:1093-1098.

30. Cho JH, Kilfoil PJ, Zhang R, et al. Reverse electrical remodeling in rats with heart failure and preserved ejection fraction. JCI Insight. 2018;3:e121123.

31. Schleifer H, Doleschal B, Lichtenegger M, et al. Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca²⁺ entry pathways. Br J Pharmacol. 2012;167:1712-1722.

32. Kitajima N, Numaga-Tomita T, Watanabe M, et al. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. Sci Rep. 2016;6:e37001.

33. Numaga-Tomita T, Kitajima N, Kuroda T, et al. TRPC3-GEF-H1 axis mediates pressure overload-induced cardiac fibrosis. Sci Rep. 2016;6:e39383.

34. Kitajima N, Watanabe K, Morimoto S, et al. TRPC3-mediated Ca²⁺ influx contributes to Rac1-mediated production of reactive oxygen species in MLP-deficient mouse hearts. Biochem Biophys Res Commun. 2011;409:108-113.

35. Miyazono KI, Moriwaki S, Ito T, Kurisaki A, Asashima M, Tanokura M. Hydrophobic patches on SMAD2 and SMAD3 determine selective binding to cofactors. Sci Signal. 2018;11:1-14.

36. Wang S, Wang C, Turdi S, Richmond KL, Zhang Y, Ren J. ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1α deacetylation. Int J Obes (Lond). 2018;42:1073-1087.

37. Kim EN, Kim MY, Lim JH, et al. The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system. Atherosclerosis. 2018;270:123-131.

38. Chang Y-C, Lin C-W, Hsieh M-C, et al. High mobility group B1 up-regulates angiogenic and fibrogenic factors in human retinal pigment epithelial ARPE-19 cells. Cell Signal. 2017;40:248-257.

39. Karbasforooshan H, Karimi G. The role of SIRT1 in diabetic retinopathy. VBiomed. Pharmacother. 2018;97:190-194.

40. Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The role of sirtuins in antioxidant and redox signaling. Antioxid Redox Signal. 2018;28:643-661.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Han L, Tang Y, Li S, et al. Protective mechanism of SIRT1 on Hcy-induced atrial fibrosis mediated by TRPC3. J Cell Mol Med. 2020;24:488-510. [https://doi.org/10.1111/jcmm.14757](https://doi.org/10.1111/jcmm.14757)